Summary
Phospho-specific antibodies have become very useful reagents for study of signal transduction pathways. This chapter describes the production of phospho-specific antibodies and their use to assess individual phosphorylation events in vivo in cells. The first step involves the synthesis of peptides (12–15 residues), where the phosphorylation site is centrally located, and a cysteine residue is incorporated at either the N- or C-terminus of the peptide to facilitate coupling it to an immunogenic carrier protein. No special immunization protocols are required to generate phospho-specific antibodies. Typically, animals of choice are immunized twice, several weeks apart, and enzyme-linked immunosorbent assay is used to determine the relative titer of sera against phosphorylated and nonphosphorylated peptides. Where the titer against phosphorylated peptides is much greater than nonphosphorylated peptides, the sera can be used at appropriate dilutions without further processing. In case a significant level of antibodies specific to the nonphosphorylated peptide is present in the antisera, an enhancement step is used to obtain a useful phospho-specific antibody. Although these enhanced antisera are suitable for many applications, there may be circumstances where affinity-purified antibodies are required. These antibodies can be used to detect a particular phosphorylation event in vivo using Western blotting, immunoprecipitation, and immunofluorescence.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Scully, R. and Livingston, D. M. (2000) In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408, 429–432.
Gatei, M., Scott, S., Fillipovitch, I., et al. (2000) Role of ATM in DNA-damage induced phosphorylation of BRCA1. Cancer Res. 60, 3299–3304.
Gatei, M., Zhou, B. B., Hobson, K., Shaun, S., Young, D., and Khanna, K. K (2001) ATM and ATR phosphorylate distinct and overlapping sites on Brca1: in vivo assessment using phospho-specific antibodies manner. J. Biol. Chem. 276, 17,276–17,280.
Chenevix-Trench, G., Spurdle, A. B., Gatei, M., et al. (2002) Dominant negative ATM mutations in breast cancer families. J. Natl. Cancer Inst. 94, 205–215.
Lee, A. C. J., Powell, J. E., Tregear, G. W., Niall, H. D., and Stevens, V. C. (1980) A method for preparing b-hCG COOH peptide-carrier conjugates of predictable composition. Mol. Immunol. 17, 749.
Schaaper, W. M. M., Lankhof, H., Puijk, W., and Meloen, R. H. (1989) Manipulation of antipeptide immune response by varying the coupling of the peptide with the carrier protein. Mol. Immunol. 26, 81–85.
Palfreyman, J. W., Aitcheson T. C., and Taylor, P. (1984) Guidelines for the production of polypeptide specific antisera using small synthetic oligopeptides as immunogens. J. Immunol. Methosds 75, 383–393.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press Inc.
About this protocol
Cite this protocol
Khanna, K.K., Gatei, M., Tribbick, G. (2006). Phospho-Specific Antibodies as a Tool to Study In Vivo Regulation of BRCA1 After DNA Damage. In: Brooks, S.A., Harris, A. (eds) Breast Cancer Research Protocols. Methods in Molecular Medicine, vol 120. Humana Press, Totowa, NJ. https://doi.org/10.1385/1-59259-969-9:441
Download citation
DOI: https://doi.org/10.1385/1-59259-969-9:441
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-58829-191-2
Online ISBN: 978-1-59259-969-1
eBook Packages: Springer Protocols